Research programme: neurological and neuromuscular disorder therapeutics - Ascidian Therapeutics
Latest Information Update: 27 Oct 2023
At a glance
- Originator Ascidian Therapeutics
- Class RNA
- Mechanism of Action RNA modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Neurological disorders; Neuromuscular disorders
Most Recent Events
- 12 Oct 2023 Early research in Neurological disorders in USA (unspecified route) prior to October 2023 (Ascidian Therapeutics pipeline October 2023)
- 12 Oct 2023 Early research in Neuromuscular disorders in USA (unspecified route) prior to October 2023 (Ascidian Therapeutics pipeline October 2023)